Biomarin Pharmaceutical (BMRN) traded down -1.2 % during a 24 hours period ending at 12:28 AM Central Europe on Tuesday 27th. One Biomarin Pharmaceutical stock can currently be bought for about USD 55.75 on popular exchanges. Current supply of Biomarin Pharmaceutical stocks is 193.6 mn. Biomarin Pharmaceutical has a current market capitalization of USD 10.8 bn and approximately USD 94.2 mn worth of Biomarin Pharmaceutical was traded on exchanges in the last 24 hours. Since last month end, Biomarin Pharmaceutical has traded -8.8 % down. Simple moving average of last 200 days is at USD 58.46. The highest price of past 52 weeks was recorded at USD 70.98 on 08/12/2026. 52 weeks low was at USD 49.26 on 05/18/2026.
Here is how related stocks have performed in the past 24 hours:
Rpm (RPM) traded down -2.93 % and now trades at USD 97.94. Current market capitalisation for Rpm is USD 12.6 bn. Current price/earnings ratio for Rpm is 18.32.
Toll Brothers (TOL) traded down -0.84 % and now trades at USD 140.4. Current market capitalisation for Toll Brothers is USD 12.9 bn. Current price/earnings ratio for Toll Brothers is 11.18.
American (AFGE) traded down -0.81 % and now trades at USD 15.4. Current market capitalisation for American is USD 12.7 bn. American has a current price to earnings ratio of 12.61.
Mccormick & (MKC) traded down -1.21 % and now trades at USD 47.97. Mccormick & has a market capitalisation of USD 12.9 bn. Current price/earnings ratio for Mccormick & is 8.65.
Penumbra (PEN) traded down -0.18 % and now trades at USD 325.22. Penumbra has a market capitalisation of USD 12.8 bn. Current price/earnings ratio for Penumbra is 79.93.
About Biomarin Pharmaceutical
BioMarin Pharmaceutical Inc. is a health care biotechnology company with its base in San Rafael, United States. The company specializes in developing and commercializing therapeutic enzyme products. It has applied its proprietary enzyme technology to create products for lysosomal storage diseases and for the treatment of serious burns. Additionally, through its subsidiaries, BioMarin provides analytical and diagnostic products and services in the field of carbohydrate biology. You can find more information about the company and its offerings on their website, www.biomarin.com , and they are listed on the Nasdaq stock exchange. The initial public offering (IPO) for BioMarin Pharmaceutical took place on July 23, 1999.
